GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Shiller PE Ratio

Omeros (FRA:3O8) Shiller PE Ratio : (As of May. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Omeros Shiller PE Ratio Historical Data

The historical data trend for Omeros's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Shiller PE Ratio Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Omeros's Shiller PE Ratio

For the Biotechnology subindustry, Omeros's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Shiller PE Ratio falls into.



Omeros Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Omeros's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Omeros's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.138/129.4194*129.4194
=-0.138

Current CPI (Dec. 2023) = 129.4194.

Omeros Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.390 99.695 -0.506
201406 -0.390 100.560 -0.502
201409 -0.419 100.428 -0.540
201412 -0.495 99.070 -0.647
201503 -0.471 99.621 -0.612
201506 -0.392 100.684 -0.504
201509 -0.472 100.392 -0.608
201512 -0.477 99.792 -0.619
201603 -0.485 100.470 -0.625
201606 -0.285 101.688 -0.363
201609 -0.303 101.861 -0.385
201612 -0.427 101.863 -0.543
201703 -0.318 102.862 -0.400
201706 -0.294 103.349 -0.368
201709 -0.134 104.136 -0.167
201712 -0.287 104.011 -0.357
201803 -0.503 105.290 -0.618
201806 -0.599 106.317 -0.729
201809 -0.694 106.507 -0.843
201812 -0.422 105.998 -0.515
201903 -0.443 107.251 -0.535
201906 -0.257 108.070 -0.308
201909 -0.300 108.329 -0.358
201912 -0.522 108.420 -0.623
202003 -0.480 108.902 -0.570
202006 -0.542 108.767 -0.645
202009 -0.560 109.815 -0.660
202012 -0.493 109.897 -0.581
202103 -0.479 111.754 -0.555
202106 -0.382 114.631 -0.431
202109 -0.306 115.734 -0.342
202112 3.965 117.630 4.362
202203 -0.481 121.301 -0.513
202206 -0.464 125.017 -0.480
202209 -0.283 125.227 -0.292
202212 1.935 125.222 2.000
202303 -0.504 127.348 -0.512
202306 -0.545 128.729 -0.548
202309 -0.562 129.860 -0.560
202312 -0.138 129.419 -0.138

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Omeros  (FRA:3O8) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Omeros Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Omeros's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros (FRA:3O8) Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines